{
  "response": {
    "text": "The ingredient in the clinical trial NCT02294461 that starts with the letter \"E\" and was part of the more effective regimen is **Enzalutamide**. This trial, also known as Asian PREVAIL, evaluated the efficacy and safety of oral Enzalutamide in patients with progressive metastatic prostate cancer. Enzalutamide is an androgen receptor inhibitor.\n\nTo determine the patent expiration date for Enzalutamide (brand name Xtandi), one would typically consult the FDA's Orange Book, which provides information on approved drug products, including patent and exclusivity data. Patents generally expire 20 years from the filing date. However, various factors like patent term extensions (PTE) can affect the expiration date.\n\nAccording to a drug patent expiration list, a patent for Xtandi (Enzalutamide) is set to expire in **2027**.",
    "citations": []
  }
}